Marcus Bosenberg

Marcus Bosenberg is a tumor immunologist whose laboratory has characterized TIGIT as a key co-inhibitory receptor on exhausted T cells in the tumor microenvironment and has explored the biology underlying the synergistic activity of combined anti-TIGIT and anti-PD-1 blockade. His preclinical studies of TIGIT biology informed several early-phase clinical trials evaluating tiragolumab (anti-TIGIT) and vibostolimab in NSCLC and other solid tumors. He has also developed novel mouse models for studying combination checkpoint inhibitor efficacy and resistance mechanisms.